OpGen | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.06.

EBIT: As of FY2025 Q3, the actual value is USD -702.19 K.

Segment Revenue

• Listing Sponsorship Services: Revenue of $4,000,000 was recognized for the nine months ended September 30, 2025, from a single contract to provide listing sponsorship and consulting services.

Operational Metrics

• Net Income: The company reported a net income of $2,493,129 for the nine months ended September 30, 2025, compared to $7,642,696 for the same period in 2024.
• Operating Expenses: Total operating expenses decreased by approximately 57% to $1,822,256 for the nine months ended September 30, 2025, from $4,272,659 in the same period in 2024.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities was - $978,685 for the nine months ended September 30, 2025, compared to - $4,637,508 for the same period in 2024.
• Free Cash Flow: Not explicitly stated, but the net decrease in cash and cash equivalents was - $896,442 for the nine months ended September 30, 2025.

Unique Metrics

• Accounts Receivable: At September 30, 2025, accounts receivable from one customer represented 99% of total accounts receivable.

Future Outlook and Strategy

• Core Business Focus: The company is repositioning itself to operate in the financial services and technology industry, focusing on listing sponsorship and consultancy services, and entering the financial technology industry with digital investment banking activities.
• Non-Core Business: The company has scaled down its legacy operations in precision medicine and is focusing on its new strategic direction in financial services.
• Priority: The company plans to fund its operations primarily through financing arrangements with AEI Capital Ltd. until its operating business can sustain itself.